Idarubicin (hydrochloride)
Idarubicin (hydrochloride) structure
|
Common Name | Idarubicin (hydrochloride) | ||
|---|---|---|---|---|
| CAS Number | 57852-57-0 | Molecular Weight | 533.955 | |
| Density | N/A | Boiling Point | 725.4ºC at 760 mmHg | |
| Molecular Formula | C26H28ClNO9 | Melting Point | 183-185ºC | |
| MSDS | Chinese USA | Flash Point | 392.5ºC | |
| Symbol |
GHS06, GHS08 |
Signal Word | Danger | |
|
Breakthrough Fusarium solani infection in a patient with acute myeloid leukemia receiving posaconazole prophylaxis.
Ann. Hematol. 93(6) , 1079-81, (2014)
|
|
|
A yeast-based assay identifies drugs that interfere with immune evasion of the Epstein-Barr virus.
Dis. Model Mech. 7(4) , 435-44, (2014) Epstein-Barr virus (EBV) is tightly associated with certain human cancers, but there is as yet no specific treatment against EBV-related diseases. The EBV-encoded EBNA1 protein is essential to maintain viral episomes and for viral persistence. As such, EBNA1 ... |
|
|
Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia.
Leukemia 28(7) , 1543-5, (2014)
|
|
|
HLA-partially matched cellular therapy (stem-cell microtransplantation) for acute myeloid leukaemia: description of four cases.
Br. J. Haematol. 165(4) , 580-1, (2014)
|
|
|
A randomized trial of prophylactic palifermin on gastrointestinal toxicity after intensive induction therapy for acute myeloid leukaemia.
Br. J. Haematol. 167(5) , 618-25, (2014) Gastrointestinal toxicity, including oral mucositis, is a frequent complication of intensive combination chemotherapy for acute myeloid leukaemia (AML) and contributes substantially to treatment-related mortality. We conducted a placebo-controlled randomized ... |
|
|
A Phase 2 study of bortezomib combined with either idarubicin/cytarabine or cytarabine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: a report from the Children's Oncology Group.
Pediatr. Blood Cancer 61(10) , 1754-60, (2014) This Phase 2 study tested the tolerability and efficacy of bortezomib combined with reinduction chemotherapy for pediatric patients with relapsed, refractory or secondary acute myeloid leukemia (AML). Correlative studies measured putative AML leukemia initiat... |
|
|
Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study.
Ann. Hematol. 93(12) , 2001-10, (2014) Activating internal tandem duplication (ITD) mutations in the fms-like tyrosine kinase 3 (FLT3) gene (FLT3-ITD) are associated with poor outcome in acute myeloid leukemia, but their prognostic impact in acute promyelocytic leukemia (APL) remains controversial... |
|
|
A genome-wide single-nucleotide polymorphism-array can improve the prognostic stratification of the core binding factor acute myeloid leukemia.
Am. J. Hematol. 87(10) , 961-8, (2012) Core binding factor (CBF) AML with the D816 C-KIT gene mutation demonstrate inferior treatment outcomes. However, the remaining cases without the D816 C-KIT mutation imply a requirement of more sophisticated dissection of the patients according to their progn... |
|
|
Decreased survival in normal karyotype AML with single-nucleotide polymorphisms in genes encoding the AraC metabolizing enzymes cytidine deaminase and 5'-nucleotidase.
Am. J. Hematol. 88(12) , 1001-6, (2013) De novo acute myeloid leukemia with normal karyotype (NK-AML) comprises a large group of patients with no common cytogenetic alterations and with a large variation in treatment response. Single-nucleotide polymorphisms (SNPs) in genes related to the metabolis... |
|
|
Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response.
Blood 120(23) , 4649-52, (2012) Mutations of genes encoding isocitrate dehydrogenase (IDH1 and IDH2) have been recently described in acute myeloid leukemia (AML). Serum and myeloblast samples from patients with IDH-mutant AML contain high levels of the metabolite 2-hydroxyglutarate (2-HG), ... |